# KLOW Peptide vs GLOW: How the Two Peptide Blends Compare

> KLOW vs GLOW: a clinical comparison of the four-peptide KLOW blend and the three-peptide GLOW blend — what KPV adds to the stack and where the evidence gap is identical for both.

KLOW peptide adds KPV as a fourth arm to the three-component GLOW blend. Here is what that changes — and what it does not change about the evidence gap.

## In plain English

KLOW vs GLOW is a comparison between two related research blends. GLOW contains three peptides: GHK-Cu, BPC-157, and TB-500. KLOW contains those same three plus a fourth: KPV. KPV is a short anti-inflammatory peptide (Lys-Pro-Val) derived from the C-terminal end of alpha-MSH (alpha-melanocyte-stimulating hormone). It adds an explicit anti-inflammatory arm to the stack and carries a gut-specific delivery mechanism via a transporter called PepT1 (SLC15A1). That is the structural difference between KLOW and GLOW.

Beyond the composition difference, the evidence gap is the same for both blends: neither GLOW nor KLOW has been tested as a combination in any controlled study. All efficacy claims for both rest on the single-component literature. This comparison sets out the composition side by side, explains what KPV adds mechanistically, and records the parallel evidence limitations honestly.

## Side-by-side composition

| Component | KLOW (4 peptides) | GLOW (3 peptides) |
|---|---|---|
| **KPV** (anti-inflammatory) | Yes — 10 mg | No |
| **GHK-Cu** (matrix remodeling) | Yes — 50 mg | Yes |
| **BPC-157** (angiogenesis) | Yes — 10 mg | Yes |
| **TB-500** (cell migration) | Yes — 10 mg | Yes |
| **Total** | 80 mg | 70 mg (typical) |

The three shared components — GHK-Cu, BPC-157 and TB-500 — occupy the same research record in both blends. The only structural difference is KPV: present in KLOW, absent from GLOW. WOLVERINE is a separate, distinct blend; this comparison does not cover it.

## What KPV adds to the KLOW vs GLOW comparison

KPV (Lys-Pro-Val, CAS 67727-97-3, MW 342.44 Da) is the C-terminal tripeptide of alpha-MSH — the fragment that carries alpha-MSH's anti-inflammatory activity in a minimal, transporter-accessible form. Its primary published mechanism is inhibition of NF-kappaB p65/RelA nuclear import and MAP-kinase inflammatory signaling (suppressing TNF-alpha, IL-6, IL-1beta and IL-8) in intestinal epithelial and immune cells at nanomolar concentrations [3]. It is transported into inflamed gut tissue via PepT1 (SLC15A1), which is upregulated in inflamed mucosa — a targeting mechanism that gives KPV preferential uptake precisely where inflammation is highest.

In DSS-induced and TNBS-induced mouse colitis models, oral KPV at 100 micromolar in drinking water reduced disease severity [3].

What this adds to the GLOW three-arm stack: an explicit upstream anti-inflammatory signal at the cytokine-suppression level, and a gut-selective delivery route. The GLOW components do have anti-inflammatory activity — GHK-Cu modulates antioxidant and anti-inflammatory gene sets [5], and BPC-157 is cytoprotective for gut mucosa in rodent models — but neither carries a dedicated cytokine-suppression mechanism equivalent to KPV's NF-kappaB inhibition. Community users who describe the four-arm KLOW blend as feeling more anti-inflammatory than the three-arm GLOW stack are likely experiencing (or perceiving) this added arm — though that is anecdotal community reporting, not a controlled comparison study.

The KLOW vs GLOW question reduces to: do you want the dedicated NF-kappaB / MAPK anti-inflammatory arm with PepT1-mediated gut uptake? If so, KLOW; if not, GLOW. That is a mechanistic framing, not a clinical recommendation.

## What does not change: the evidence gap is the same for both

Adding KPV to the three-arm GLOW stack does not resolve the fundamental evidence limitation: no controlled study has tested GLOW as a combination, and no controlled study has tested KLOW as a combination. The evidence gap is identical in kind for both — all claims rest on single-component research, mostly in cells and rodents.

For the shared components, the evidence picture is the same in both blends:
- TB-500 / thymosin beta-4: foundational wound data for the full-length native protein; limited data for the short TB-500 fragment specifically [1].
- BPC-157: extensive rodent tissue-repair literature; one 2025 small human IV safety pilot [6]; no efficacy human trial.
- GHK-Cu: robust topical cosmetic and dermatology human data [4]; in vitro transcriptomic data [5]; no systemic clinical trial.

The WADA S2 prohibition on thymosin beta-4 applies to both blends — both contain TB-500.

---

A calm clinical reference on the component literature — four peptides set out arm by arm, each finding kept to its own study.